THERAPEUTIC COMPOSITIONS INCLUDING PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES AND USES THEREOF
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of phenazine-3-one and/or phenothiazine-3-one derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to phenazine-3-one or phenothiazine-3-one derivatives and uses of the same. In some embodiments, the aromatic-cationic peptide comprises D-Arg-2′6′-Dmt-Lys-Phe-NH 2 .
1 . A composition comprising a phenazine-3-one and/or phenothiazine-3-one derivative as described in Section I in combination with one or more aromatic-cationic peptides disclosed in Section II.
2 . The composition of claim 1 , further comprising one or more additional active agents such as cyclosporine, a cardiac drug, an anti-inflammatory, an anti-hypertensive drug, an antibody, an ophthalmic drug, an antioxidant, a metal complexer, and an antihistamine.
3 . A method for:
(a) treating or preventing a disease or condition,
(b) reducing CD36 expression in a subject in need thereof,
(c) treating or preventing a disease or condition characterized by CD36 elevation in a subject in need thereof,
(d) reducing oxidative damage in a removed organ or tissue,
(e) preventing the loss of dopamine-producing neurons in a subject in need thereof,
(f) reducing oxidative damage associated with a neurodegenerative disease in a subject in need thereof,
(g) preventing or treating a burn injury in a subject in need thereof,
(h) treating or preventing mechanical ventilation-induced diaphragm dysfunction in a subject in need thereof,
(i) treating or preventing no reflow following ischemia-reperfusion injury in a subject in need thereof,
(j) preventing norepinephrine uptake in a subject in need of analgesia,
(k) treating or preventing drug-induced peripheral neuropathy or hyperalgesia in a subject in need thereof,
(l) inhibiting or suppressing pain in a subject in need thereof, or
(m) treating atherosclerotic renal vascular disease (ARVD) in a subject in need thereof, comprising administering a therapeutically effective amount of a composition comprising a phenazine-3-one and/or phenothiazine-3-one derivative as described in Section I, in combination with one or more aromatic-cationic peptides disclosed in Section II, and optionally one or more additional active agents such as cyclosporine, a cardiac drug, an anti-inflammatory, an anti-hypertensive drug, an antibody, an ophthalmic drug, an antioxidant, a metal complexer, and an antihistamine.
4 . The method of claim 3 , wherein:
(a) the disease or condition comprises a neurological or neurodegenerative disease or condition, ischemia, reperfusion, hypoxia, atherosclerosis, ureteral obstruction, diabetes, complications of diabetes, arthritis, liver damage, insulin resistance, diabetic nephropathy, acute renal injury, chronic renal injury, acute or chronic renal injury due to exposure to nephrotoxic agents and/or radiocontrast dyes, hypertension, metabolic syndrome, an ophthalmic disease or condition such as dry eye, diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, oxygen-induced retinopathy, cardiomyopathy, ischemic heart disease, heart failure, hypertensive cardiomyopathy, vessel occlusion, vessel occlusion injury, myocardial infarction, coronary artery disease, oxidative damage,
(b) the disease or condition comprises mitochondrial permeability transition,
(c) the neurological or neurodegenerative disease or condition comprises Alzheimer's disease, Amvotrophic Lateral Sclerosis (ALS), Parkinson's disease, Huntington's disease or Multiple Sclerosis,
(d) the subject is suffering from ischemia or has an anatomic zone of no-reflow in one or more of cardiovascular tissue, skeletal muscle tissue, cerebral tissue and renal tissue,
(e) the subject is diagnosed as having, suspected of having, or at risk of having atherosclerosis, inflammation, abnormal angiogenesis, abnormal lipid metabolism, abnormal removal of apoptotic cells, ischemia such as cerebral ischemia and myocardial ischemia, ischemia-reperfusion, ureteral obstruction, stroke, Alzheimer's Disease, diabetes, diabetic nephropathy, or obesity
(f) the removed organ comprises a heart, lung, pancreas, kidney, liver, or skin, or
(g) wherein the subject is diagnosed as having, suspected of having, or at risk of having Parkinson's disease or ALS.
5 .- 23 . (canceled)
24 . A peptide conjugate comprising a phenazine-3-one or phenothiazine-3-one derivative conjugated to an aromatic-cationic peptide, wherein the aromatic-cationic peptide is selected from the group consisting of: Phe-D-Arg-Phe-Lys-NH 2 , D-Arg-2′6′-Dmt-Lys-Phe-NH 2 , 2′,6′-dimethyl-Tyr-D-Arg-Phe-Lys-NH 2 , a peptide of Table A, Table 5, Table 6 or Table 7; and wherein the phenazine-3-one or phenothiazine-3-one derivative is a compound described in Section I.
25 . A peptide conjugate according to claim 24 , wherein:
(a) the phenazine-3-one or phenothiazine-3-one derivative is conjugated to the aromatic-cationic peptide by a linker,
(b) the phenazine-3-one or phenothiazine-3-one derivative and aromatic-cationic peptide are chemically bonded,
(c) the phenazine-3-one or phenothiazine-3-one derivative and aromatic-cationic peptide are physically bonded, or
(d) the aromatic-cationic peptide and the phenazine-3-one or phenothiazine-3-one derivative are linked using a labile linkage that is hydrolyzed in vivo to uncouple the aromatic-cationic peptide and the phenazine-3-one or phenothiazine-3-one derivative.
26 .- 28 . (canceled)
29 . A peptide conjugate according to claim 25 , wherein the labile linkage comprises an ester linkage.
30 . A method for delivering an aromatic-cationic peptide and/or a phenazine-3-one or phenothiazine-3-one derivative to a cell, the method comprising contacting the cell with the peptide conjugate of claim 29 .
31 . A method according claim 30 , wherein:
(a) the phenazine-3-one or phenothiazine-3-one derivative is conjugated to the aromatic-cationic peptide by a linker,
(b) the phenazine-3-one or phenothiazine-3-one derivative and aromatic-cationic peptide are chemically bonded
(c) the phenazine-3-one or phenothiazine-3-one derivative and aromatic-cationic peptide are physically bonded, or
(d) the aromatic-cationic peptide and the phenazine-3-one or phenothiazine-3-one derivative are linked using a labile linkage that is hydrolyzed in vivo to uncouple the aromatic-cationic peptide and the phenazine-3-one or phenothiazine-3-one derivative.
32 .- 34 . (canceled)
35 . A method according claim 30 , wherein the labile linkage comprises an ester linkage.
36 . A method for treating, ameliorating or preventing a medical disease or condition in a subject in need thereof, comprising administering a therapeutically effective amount of a composition of claim 24 to the subject thereby treating, amelioration or preventing the medical disease or condition.
37 . A method according to claim 36 , wherein:
(a) the medical disease or condition is characterized by mitochondrial permeability transition,
(b) the medical disease or condition comprises a neurological or neurodegenerative disease or condition, ischemia, reperfusion, hypoxia, atherosclerosis, ureteral obstruction, diabetes, complications of diabetes, arthritis, liver damage, insulin resistance, diabetic nephropathy, acute renal injury, chronic renal injury, acute or chronic renal injury due to exposure to nephrotoxic agents and/or radiocontrast dyes, hypertension, metabolic syndrome, an ophthalmic disease or condition such as dry eye, diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, oxygen-induced retinopathy, cardiomyopathy, ischemic heart disease, heart failure, hypertensive cardiomyopathy, vessel occlusion, vessel occlusion injury, myocardial infarction, coronary artery disease, oxidative damage,
(c) the neurological or neurodegenerative disease or condition comprises Alzheimer's disease, Amvotrophic Lateral Sclerosis (ALS), Parkinson's disease, Huntington's disease or Multiple Sclerosis, or
(d) the subject is suffering from ischemia or has an anatomic zone of no-reflow in one or more of cardiovascular tissue, skeletal muscle tissue, cerebral tissue and renal tissue.
38 .- 40 . (canceled)
41 . A method for reducing CD36 expression in a subject in need thereof or treating, ameliorating or preventing a disease or condition characterized by CD36 elevation in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 24 .
42 . (canceled)
43 . The method according to claim 41 , wherein the subject is diagnosed as having, is suspected of having, or at risk of having atherosclerosis, inflammation, abnormal angiogenesis, abnormal lipid metabolism, abnormal removal of apoptotic cells, ischemia such as cerebral ischemia and myocardial ischemia, ischemia-reperfusion, ureteral obstruction, stroke, Alzheimer's disease, diabetes, diabetic nephropathy, or obesity.
44 . A method for reducing oxidative damage in a removed organ or tissue, comprising administering to the removed organ or tissue a therapeutically effective amount of the composition of claim 24 .
45 . The method according to claim 44 , wherein the removed organ comprises a heart, lung, pancreas, kidney, liver, or skin.
46 . A method for:
(a) preventing the loss of dopamine-producing neurons in a subject in need thereof,
(b) reducing oxidative damage associated with a neurodegenerative disease in a subject in need thereof,
(c) preventing or treating a burn injury in a subject in need thereof,
(d) treating or preventing mechanical ventilation-induced diaphragm dysfunction in a subject in need thereof,
(e) treating or preventing no-reflow following ischemia-reperfusion injury in a subject in need thereof,
(f) for preventing norepinephrine uptake in a mammal in need of analgesia,
(g) treating, ameliorating or preventing drug-induced peripheral neuropathy or hyperalgesia in a subject in need thereof,
(h) inhibiting or suppressing pain in a subject in need thereof, or
(i) treating atherosclerotic renal vascular disease (ARVD) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the composition of claim 24 .
47 . The method of claim 46 , wherein the subject is diagnosed as having, suspected of having, or at risk of having Parkinson's disease or ALS.
48 . (canceled)
49 . The method according to claim 46 , wherein the neurodegenerative disease comprises Alzheimer's disease, Parkinson's disease, or ALS.
50 .- 56 . (canceled)